PTC (NASDAQ:PTC – Free Report) had its price objective upped by JPMorgan Chase & Co. from $200.00 to $210.00 in a report ...

PTC (NASDAQ: PTC) today announced that it has partnered with Microsoft and Volkswagen Group to develop a generative ...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...

Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of PTC Inc. (NASDAQ:PTC – Free Report) in the ...

PTC Therapeutics surges 21% after entering exclusive global collaboration with Novartis for Huntington's disease program ...

RBC Capital has upgraded PTC Therapeutics (PTCT) to outperform from sector perform on the company’s deal with Novartis (NVS) for its Huntington’s disease program. Read more here.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price was down 3.4% on Friday . The company traded as low as ...

A groundbreaking drug, a massive deal, and a stock rally--this could reshape neurodegenerative disease treatments.

StockNews.com downgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a ...

Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price rose 4.8% on Tuesday after Robert W. Baird raised their price target on the stock from $48.00 to $52.00. Robert W. Baird currently ...